A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples